Retinal Vein Occlusion as the Surrogate Marker for Premature Brain Aging in Young Patients

Kwan Hyuk Cho,1,2 Chi Kyung Kim,3 Kyungmi Oh,3 Seung-Won Oh,4 Kyu Hyung Park,1 and Sang Jun Park1

1Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2HanGil Eye Hospital, Incheon, Republic of Korea
3Department of Neurology, Korea University Guro Hospital and Korea University College of Medicine, Seoul, Republic of Korea
4Department of Family Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea

Correspondence: Sang Jun Park, Department of Ophthalmology, Seoul National University Bundang Hospital, 82, Gumiro 173 beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea. sangjunpark@snu.ac.kr.

PURPOSE. We investigated cerebral small vessel disease (SVD) in patients with incidental retinal vein occlusion (RVO).

METHODS. This retrospective, case-control, observational trial included 125 patients with RVO who underwent brain magnetic resonance imaging (MRI) and 1105 age-matched controls who underwent comprehensive medical interviews and MRI. Underlying cardiovascular diseases and MRI findings were investigated in the patients with RVO according to age (<60 or ≥60 years) and RVO occlusion level (central or branch). The characteristics of underlying cardiovascular disease and MRI findings were compared between the younger patients with RVO and age-matched controls. The cerebrovascular burden also was assessed in the younger patients with RVO.

RESULTS. The mean age of the patients with RVO was 63.9 ± 12.1 years and the predominant underlying disease was hypertension (72/125, 58%). The older RVO group had a longer history of hypertension and less smoking history. The prevalence of cerebral SVD in the RVO group was 54% (68/125), and was significantly higher in older than in younger patients with RVO (62% [53/86] vs. 38% [15/39], P = 0.016). However, the latter had a significantly higher prevalence of cerebral SVD than their age-matched controls (38% [15/39] vs. 4% [47/1105], P < 0.001). There was no difference in prevalence of cerebral SVD between the central and branch RVO groups (P = 0.478).

CONCLUSIONS. Cerebral SVD presented frequently in patients with RVO and was magnified in young patients, suggesting that RVO is a surrogate marker for cerebral SVD.

Keywords: retinal vein occlusion, cerebral small vessel disease, brain MRI
occlusion (n = 3), diabetic retinopathy (n = 12), inflammatory retinal disease (n = 3), or a pre-existing brain mass lesion (n = 3) were excluded. No patient had other serious ocular disease or a hematologic or inflammatory etiology for RVO. We identified the patients who also had undergone brain MRI within 1 year on either side of the first presentation of incidental RVO. We also investigated the reason for brain MRI in these patients; brain MRI sometimes was ordered by the neurologists, but was performed mostly in the absence of neurologic symptoms as part of a health screening program. A total of 125 patients with incidental RVO and results for MRI of the brain could be included in the analysis. Figure 1 shows a flow chart of the subject selection process and final dataset available for analysis.

Demographics, Medical History, and Ophthalmic Evaluation

All patients underwent a complete ophthalmic examination at the initial visit, which included slit-lamp biomicroscopy, indirect ophthalmoscopy, fundus photography (Vx-10; Kowa Optimed, Tokyo, Japan; Optos PLC, Dunfermline, Scotland, UK), and fluorescein angiography (Vx-10, Kowa Optimed). We obtained demographic information and a medical history (e.g., hypertension, diabetes mellitus, dyslipidemia, smoking, and cardiovascular disease, including acute stroke, transient ischemic attack, atrial fibrillation, and valvular heart disease) by detailed review of all patients’ medical charts to evaluate cardiovascular risk factors. We also reviewed laboratory test results (e.g., complete blood cell count, erythrocyte sedimentation rate, C-reactive protein, and blood coagulation test) in all patients to identify a specific cause for RVO. We then subcategorized the patients according to age (<60 or ≥60 years). The prevalence of cerebral SVD is different between older and younger age groups. Several well-known population-based studies of cerebral SVD selected 60 years as a cutoff value for the elderly population. Accordingly, we chose 60 years as the cutoff value for our assessment of the relationship between RVO and cerebral SVD. Further, we subcategorized the patients according to level of RVO (central or branch) and analyzed central RVO (CRVO) according to area of capillary nonperfusion (10 disc diopters on fluorescein angiography, ischemic or nonischemic) based on initial ophthalmic examination.

Age-Matched Controls for Young Patients With RVO

Age is a potent risk factor of cerebral SVD, and age-matched controls for old patients with RVO do not have clinical significance. To compare brain MRI findings between younger patients with RVO and the normal population, we retrospectively reviewed a consecutive series of 1110 neurologically healthy individuals (<60 years) who visited SNUH Healthcare System Gangnam Center for a routine health check between October 2003 and December 2004, and participated in the SNUH Gangnam Survey. We defined neurologically and ophthalmologically healthy individuals as those who had not experienced a stroke or transient ischemic attack, had no symptoms or signs of neurologic disease, had no decrease in best corrected visual acuity, and had no history of retinal disease. Five of these 1110 individuals had not undergone a brain MRI, so they were excluded, leaving 1105 asymptomatic individuals with brain MRI results and without overt neurologic or retinal disease for enrolment. Clinical information was obtained by personal interview, and each subject underwent a physical examination by a trained physician.

Evaluation of Brain MRI

We evaluated aging of the brain and the status of the vessels in patients with RVO using a 1.5 or 3.0 Tesla MRI scanner (Intera...
or Achieva; Philips, Best, The Netherlands; Signa; GE, Milwaukee, WI, USA). The 5 mm axial slices were obtained using conventional MR protocols: T1-weighted (repetition time [TR]/echo time [TE], 300/12), T2-weighted (TR/TE, 4800/100), and fluid attenuated inversion recovery (FLAIR) (TR/TE, 11,000/140) images. An additional special protocol, that is T2*-gradient-recalled echo (GRE) images (TR/TE, 724/23), was used to assess CMBs, one of the MRI markers for SVD in the brain, and diffusion-weighted MRI (TR/TE, 4800/66) was performed to evaluate acute infarction. The large vessels of the brain were visualized on time-of-flight angiographic images and fluide attenuated inversion recovery (FLAIR) (TR/TE, 300/12), T2-weighted (TR/TE, 4800/100), and T2* gradient-recalled echo (GRE) images (TR/TE, 724/23), was used to assess CMBs, one of the MRI markers for SVD in the brain, and diffusion-weighted MRI (TR/TE, 4800/66) was performed to evaluate acute infarction. The large vessels of the brain were visualized on time-of-flight angiographic images.

TABLE 1. Clinical Characteristics and Underlying Diseases in Patients With RVO

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All RVO, n = 125, 100%</th>
<th>&lt;60 y, n = 39, 31%</th>
<th>≥60 y, n = 86, 69%</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean, y</td>
<td>63.9 ± 12.1</td>
<td>50.5 ± 9.4</td>
<td>70.2 ± 6.9</td>
<td>0.001†</td>
</tr>
<tr>
<td>Sex, male, n (%)</td>
<td>57 (46%)</td>
<td>25 (64%)</td>
<td>32 (37%)</td>
<td>0.005‡</td>
</tr>
<tr>
<td>Past medical history, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>72 (58%)</td>
<td>18 (46%)</td>
<td>54 (63%)</td>
<td>0.061‡</td>
</tr>
<tr>
<td>Diabetes</td>
<td>28 (22%)</td>
<td>6 (15%)</td>
<td>22 (26%)</td>
<td>0.205‡</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>50 (40%)</td>
<td>12 (31%)</td>
<td>38 (44%)</td>
<td>0.156‡</td>
</tr>
<tr>
<td>Smoking</td>
<td>26 (21%)</td>
<td>15 (38%)</td>
<td>11 (13%)</td>
<td>0.001‡</td>
</tr>
<tr>
<td>Previous cardiovascular disease, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute stroke</td>
<td>33 (26%)</td>
<td>8 (21%)</td>
<td>25 (29%)</td>
<td>0.315‡</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>6 (5%)</td>
<td>1 (3%)</td>
<td>5 (6%)</td>
<td>0.390‡</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>28 (22%)</td>
<td>6 (15%)</td>
<td>22 (26%)</td>
<td>0.205‡</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>6 (5%)</td>
<td>1 (3%)</td>
<td>5 (6%)</td>
<td>0.390‡</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>8 (6%)</td>
<td>2 (5%)</td>
<td>6 (7%)</td>
<td>0.892‡</td>
</tr>
</tbody>
</table>

The data are reported as numbers (percentages). All P values are for comparisons between subjects aged <60 and ≥60 years.

* P < 0.05.
† Mann-Whitney U test.
‡ Fisher’s exact test.

Statistical Analysis

Interobserver agreement for brain MRI between the two investigators (KHC, CCK) was excellent (Cohen’s κ = 0.845). The statistical analysis was performed using SPSS version 22.0 for Windows (IBM Corp., Armonk, NY, USA). P values < 0.05 were considered to be statistically significant.

RESULTS

Demographic and Clinical Characteristics

We included a total of 125 patients with RVO (57 men, 68 women), comprising 38 in the central RVO group and 87 in the branch RVO group. The mean age was 63.9 (range, 20–89 years) and 86 patients were older than 60 years at the time of their initial diagnosis. Hypertension was the most common underlying condition (72 patients, 58%), followed by dyslipidemia and diabetes mellitus. There was no difference in the prevalence of diabetes mellitus and dyslipidemia between the groups when categorized by age; however, patients younger than 60 years were more likely to smoke (P = 0.001) and less likely to have hypertension (P = 0.061) than their older counterparts. In addition, patients showed a similar incidence of previous cardiovascular diseases, including acute stroke, transient ischemic attack, ischemic heart disease, and valvular heart disease in the groups of age categorization (Table 1).

Brain MRI Findings According to Age in Patients With RVO

We evaluated the reasons for brain MRI in all subjects. Nine patients (7%) visited the emergency room with neurologic symptoms, 14 (11%) visited the outpatient clinic in our neurology department with neurologic symptoms, and the others (82%) underwent brain MRI in the absence of neurologic symptoms as part of a comprehensive health screening program. Therefore, most information was gathered incidentally. The overall prevalence rates of acute cerebral infarction (concurrent ischemic brain infarct) and cerebral SVD in the patients with RVO were 5% and 54%, respectively. Patients with RVO who were aged 60 years or older showed a similar prevalence of acute cerebral infarction (P = 0.375), but their prevalence of cerebral SVD was significantly higher than that in patients younger than 60 years (62% [n = 55] vs. 38% [n
between subjects aged < 60 and ≥ 60 years. Although the patients over 60 years old had significantly more grade 3 WMH (P = 0.007), CMBs and silent lacunar infarcts did not differ according to age category (P = 0.379 and P = 0.409, respectively; Table 2; Fig. 2).

The younger patients with RVO (mean age, 50.5 ± 9.4 years) had cardiovascular risk factors similar to those in the control group. However, the younger patients with RVO had a significantly higher overall prevalence of SVD (P ≤ 0.001), including significantly higher prevalence rates of WMH, CMBs, and silent lacunar infarcts (all P < 0.05; Table 3; Fig. 3).

### Brain MRI Findings According to Anatomy in Patients With RVO

The frequencies of acute cerebral infarction and cerebral SVD were similar between the central and branch RVO groups (P = 0.873 and P = 0.654, respectively). Further, the distribution of subtypes of cerebral SVD, including WMH, CMB, and silent lacunar infarct, was not significantly different between the two groups (Supplementary Table S1). In addition, prevalence or distribution of subtypes of cerebral SVD was not significantly different between ischemic and nonischemic CRVO (Supplementary Table S2).

### DISCUSSION

We evaluated fundus photography, fluorescein angiography, and brain MRI results in 125 patients with incidental RVO, and compared the findings of these investigations in young patients with RVO aged < 60 years to those in an age-matched control population. Although concurrent stroke was relatively common (6 of 125 patients, 5%), more than half of the patients with incidental RVO presented with cerebral SVD, which increases the risk of future cognitive impairment, ischemic stroke, and even vascular death irrespective of cardiovascular disease.  

Cerebral SVD is known to be a marker of vascular ageing and accumulation of vascular risks, and the importance of early modification of risk factors, particularly hypertension, in patients with cerebral SVD currently is emerging. RVO also is known to be a vascular disease with similar vascular risks. Accordingly, the same disease developing in separate organs could indicate a shared disease mechanism and similar underlying risk factors for the disease. However, we must look at this problem from different angles when considering our results in young patients with RVO. When we compared our young patients with RVO with an age-matched normal population with similar vascular risk factors, we found a large burden of cerebral SVD in the RVO group. This finding indicates that the relationship between RVO and SVD is not only as a marker of accumulated risk for vascular disease, but also a crucial indicator of vascular aging in individual patients. An ophthalmologic finding of RVO, especially at a relatively young age, could be an indicator of degeneration of brain vessels reflecting cerebrovascular age and not just chronicologic age.

Several recently published population-based and clinical studies have shown a relationship between retinal vascular disease and acute cerebral stroke, and suggested a higher risk of stroke in young patients with RVO. Another report has proposed that cerebral aging seems accelerated by 10 to 20 years in young patients with stroke. Furthermore, several studies have reported that cerebral SVD is associated with cognitive dysfunction and cerebrovascular accident. Although more data are needed to confirm if this is the case, when these reports are combined with our present results, it seems that RVO and cerebral SVD have a relationship with each other, and this relationship is intensified in young patients. We suggest that identification and treatment of RVO could be a gatekeeper to prevent future cognitive dysfunction and severe neurologic deficit in young patients. Given that RVO usually presents as acute vision loss that may prompt a clinic visit, the primary physician or ophthalmologist must counsel or refer for appropriate evaluation and risk modification.

There are some limitations to our study. First, we included only those patients with RVO whose brain MRI findings were available, which might be a source of selection bias. However, most brain MRI scans were incidentally performed in patients with RVO, which would minimize the likelihood of such bias. Second, there are no long-term follow-up data on the study patients, so we were not able to determine the incidence of SVD in patients with RVO. Unfortunately, we could not investigate the genetic background of patients with cerebral SVD and RVO in this study. Further evaluation is warranted in this respect. In conclusion, patients with RVO have a large
burden of cerebral SVD, which is magnified in younger patients. We believe that RVO might be a surrogate marker for SVD, especially in the young age groups. Given that young patients with SVD and RVO could be at future risk of severe cerebrovascular disease and cognitive dysfunction, early modification of vascular risk factors may be needed.

Acknowledgments

Supported by the Small Grant for Exploratory Research (SGER) of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, ICT, and Future Planning (NRF-2015R1D1A1A02062194). The funding organizations had no role in the design or conduct of this research.

Disclosure: K.H. Cho, None; C.K. Kim, None; K. Oh, None; S.-W. Oh, None; K.H. Park, None; S.J. Park, None

References

Small Vessel Disease in Retinal Vein Occlusion

IOVS | Special Issue | Vol. 58 | No. 6 | BIO87


